Windtree Therapeutics (WINT) said Monday that it regained compliance with Nasdaq's minimum bid price requirements.
The biotech company said it was notified in December that it was out of compliance with the minimum bid price rule because its share price failed to meet a minimum closing price of $1.00 or more for 30 consecutive days.
The company said it will remain under a mandatory panel monitor until March 20, 2026.
Shares of the company were up more than 39% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.